0 false false false false false false false false false false true true false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2025 - FRS102_2025 xbrli:pure xbrli:shares iso4217:GBP 13963781 2024-04-01 2025-03-31 13963781 2025-03-31 13963781 2024-03-31 13963781 2023-04-01 2024-03-31 13963781 2024-03-31 13963781 2023-03-31 13963781 bus:Director1 2024-04-01 2025-03-31 13963781 bus:Director2 2024-04-01 2025-03-31 13963781 core:WithinOneYear 2025-03-31 13963781 core:WithinOneYear 2024-03-31 13963781 core:ShareCapital 2025-03-31 13963781 core:ShareCapital 2024-03-31 13963781 core:RetainedEarningsAccumulatedLosses 2025-03-31 13963781 core:RetainedEarningsAccumulatedLosses 2024-03-31 13963781 bus:SmallEntities 2024-04-01 2025-03-31 13963781 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 13963781 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13963781 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13963781 bus:FullAccounts 2024-04-01 2025-03-31
COMPANY REGISTRATION NUMBER: 13963781

Janvin Medical Ltd

Filleted Unaudited Financial Statements

For the year ended

31 March 2025

Janvin Medical Ltd

Statement of Financial Position

31 March 2025

| 2025 | 2024
Note | £ | £ | £

Current assets

Cash at bank and in hand | 22,427 |  | 20,472

Creditors: amounts falling due within one year | 5 | 9,122 |  | 13,382
| -------- |  | --------
Net current assets |  | 13,305 | 7,090
|  | -------- | -------
Total assets less current liabilities |  | 13,305 | 7,090
|  | -------- | -------
Net assets |  | 13,305 | 7,090
|  | -------- | -------

Capital and reserves

Called up share capital |  | 2 | 2
Profit and loss account |  | 13,303 | 7,088
|  | -------- | -------
Shareholders funds |  | 13,305 | 7,090
|  | -------- | -------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the income statement has not been delivered.
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 3 December 2025 , and are signed on behalf of the board by:

Dr J Paschkowski | Dr V K Menon
Director | Director

Company registration number: 13963781

Janvin Medical Ltd

Notes to the Financial Statements

Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 28 Welton Old Road, Welton, Brough, HU15 1NU.
2. Statement of compliance
These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
(a) Basis of preparation
The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.
(b) Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax. Revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be reliably estimated. When the outcome cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable.
(c) Current & deferred tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
(d) Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Employee numbers
The average number of persons employed by the company during the year, including the directors, amounted to 2 (2024: 2).
5. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Corporation tax | 1,693 | 1,618
Directors loan accounts | 6,433 | 10,840
Other creditors | 996 | 924
| ------- | --------
| 9,122 | 13,382
| ------- | --------